Sputum and plasma adiponectin levels in clinically stable adult cystic fibrosis patients with CFTR I1234V mutation

Abstract

Sputum and plasma adiponectin levels in clinically stable adult cystic fibrosis patients with CFTRI1234V mutation Background: Cystic fibrosis (CF) lung disease is associated with chronic inflammation leading to a decrease in lung function. Adiponectin is a predominantly anti-inflammatory adipokine that may have a role in CF lung. Aims: To determine sputum and plasma adiponectin levels in clinically stable adults CF patients with CFTR I1234 V mutation, compared to plasma adiponectin levels in healthy controls and to investigate their correlations with lung function in patients with CF. Methods: A cross-sectional study comprises 17 CF patients and 18 healthy controls. Adiponectin levels were measured by magnetic bead-based multiplex assay. Results: The mean age of adult CF patients was 22.9 years± 3.8 (18-30) and13/17 (76.5%) CF patients had pancreatic sufficiency. The mean BMI in healthy controls was higher than BMI in CF patients but statistically insignificant. The mean sputum adiponectin level was significantly lower than plasma adiponectin levels in CF patients and healthy controls (p adiponectin levels between CF patients and healthy controls. The mean sputum adiponectin level was higher in CF patients with pancreatic insufficiency versus CF patients with pancreatic sufficiency (p Conclusions: Sputum adiponectin may provide a minimally invasive tool in the assessment of an inflammatory status in CF patients.